Ex-Dividend Reminder: Cencora, Amgen and Oppenheimer Holdings

Cencora (COR), Amgen (AMGN) and Oppenheimer Holdings A (OPY) go ex-dividend on 2/13/2026; COR will pay $0.60 on 3/2/26 (implying ~0.67% annualized yield and ~0.17% of a $360 share price), AMGN will pay $2.52 on 3/6/26 (implying ~2.76% annualized yield), and OPY will pay $0.18 on 2/27/26 (implying ~0.80% annualized yield). The note projects one-day theoretical price impacts of roughly -0.17% for COR, -0.69% for AMGN and -0.20% for OPY; Amgen is highlighted as a potential future Dividend Aristocrat with 14+ years of increases, and intraday moves showed COR down ~0.9%, AMGN down ~3%, and OPY down ~2.8%.

Analysis

Market structure: The ex-dividend events for COR, AMGN, and OPY are immaterial at scale (expected mechanical drops of ~0.17%, 0.69%, 0.20% on 2/13/26) but signal short-term flows as income-oriented holders rotate. AMGN (2.76% yield) attracts defensive income buyers and has structural support given 14 consecutive increases; COR (0.67%) and OPY (0.80%) are less compelling for yield-driven demand, so expect relative underperformance in a risk-off rebalancing over days–weeks.

Risk assessment: Tail risks include regulatory setbacks for AMGN (failed late-stage trials or FDA delays) and reimbursement/margin pressure for COR (distribution pricing or contract renewals) or OPY (market share losses in brokerage). Immediate risk: ex-dividend noise and 1–3 week position churn; medium-term (3–12 months): earnings/clinical catalysts for AMGN and contract renewals for COR; long-term: sector consolidation or rates-driven valuation compression across financials and healthcare services.

Trade implications: Favor AMGN as a core long (6–24 months) for income + potential Dividend Aristocrat candidacy; treat COR and OPY as tactical plays—use options to harvest premium or hedge rather than outright longs. Cross-asset: expect minimal FX/commodity impact; rising rates would compress financial brokerage multiples (negative for OPY) and modestly pressure long-duration pharma but AMGN's cash flow insulates near term.

Contrarian angles: The market may over-penalize COR and OPY for tiny dividend yields—mispricing opportunities exist if either reports stable free-cash-flow or beats earnings; conversely AMGN could be priced for perfection—a >5% downside on a clinical miss is plausible. Look for mispricings after earnings/clinical windows rather than trading purely the ex-dividend mechanical drops.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in AMGN (ticker AMGN) on a pullback of ≥3% from current levels or if the forward yield rises to ≥3.25%; target 6–24 month holding period, take-profit at +20% or stop-loss at -8%.
• Reduce COR exposure by 1–2% vs sector benchmark; if remaining long, sell 30–45 day covered calls to collect premium into the ex-dividend window or buy a 3-month put (cost ≤1% premium) if price drops >5% in a month to protect downside.
• Initiate a small tactical pair: long AMGN (size 1–2%) and short OPY (size 0.5–1%) to express defensive healthcare vs regional brokerage weakness over the next 1–3 months; hedge with 1–2% notional of index protection (e.g., buy SPX puts) if markets retest lows.
• Use options for income/defensive positioning: sell 6–8 week covered calls on AMGN around ex-dividend dates to raise yield by 100–200bps; buy 1–3 month puts on OPY if you hold shares or anticipate >10% realized vol after earnings/market dislocations.